Quantitative immunohistochemistry in lung cancer: clinical perspective.
Quantitative immunohistochemistry remains an important tool in translational lung cancer research with hopes to improve patient outcomes and avoid unnecessary therapies. Present review is aimed to summarize the use of immunohistochemical markers for improved prognostic information and prediction of treatment benefit. Several of these markers are currently explored in phase II-III clinical studies to individualize the treatment of lung cancer.
Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
Ewa
E
Szutowicz
Rafał
R
Dziadziuszko
D014408:Biomarkers, Tumor / Q000032:analysis*; D003955:Diagnostic Tests, Routine; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D011237:Predictive Value of Tests; D011379:Prognosis
D014408:Biomarkers, Tumor